The Latest Breaking News from Boston Scientific

Boston Scientific posted a mixed third quarter Wednesday, though sales of one of its key products likely grew more than 30%. BSX stock rose.

Settlement of two Australian class actions is largest in country’s history and subject to federal court approval

U.S. crude oil futures traded lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Boston Scientific's cardiology division was "on fire" in the second quarter, an analyst said Wednesday as BSX stock surged on its beat.

Johnson & Johnson (NYSE: JNJ) reported upbeat earnings for its second quarter, but lowered its FY22 guidance. Investors, meanwhile, focused on some notable insider trades.

Lawyer says settlement will provide compensation for women who suffered pain and complications from pelvic mesh

Boston Scientific's (NYSE:BSX) short percent of float has risen 25.0% since its last report. The company recently reported that it has 19.02 million shares sold short, which is 1.35% of all regular shares that are available for trading.

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.66% on an annualized basis producing an average annual return of 20.68%. Currently, Boston Scientific has a market capitalization of $54.31 billion.

Over the past 3 months, 5 analysts have published their opinion on Boston Scientific (NYSE:BSX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Boston Scientific Corporation (NYSE:BSX) has agreed to purchase Synergy Innovation Co Ltd's majority stake (~64%) of M.I.Tech Co Ltd, a publicly-traded Korean manufacturer, and distributor of medical devices for endoscopic and urologic procedures.  The deal is valued at KRW 14,500 per share, representing KRW 291.2 billion or approximately $230 million. M.I.Tech offers HANAROSTENT technology, a…

Boston Scientific (NYSE:BSX) has outperformed the market over the past 10 years by 9.09% on an annualized basis producing an average annual return of 20.41%. Currently, Boston Scientific has a market capitalization of $53.12 billion.